AstraZeneca CEO Pascal Soriot aims for 15 new drug launches by 2030
AstraZeneca CEO Pascal Soriot on Thursday unveiled ambitious plans to launch 15 new drugs by 2030 — and he’s wasting no time, with 30 Phase III trial initiations planned this year.
Soriot spies blockbuster potential in 10 of those programs, he said on the company’s quarterly earnings call, including the company’s oral SERD camizestrant in ER+/HER2- breast cancer and CinCor’s baxdrostat in hypertension.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.